10-Q: Passage Bio Eyes Merger with Remix Therapeutics Amidst Restructuring

Passage Bio announces a merger agreement with Remix Therapeutics, plans to wind down gene therapy programs, and reports significant operating losses and cash burn.

Summary

• Passage Bio is undergoing a significant strategic shift, entering into a merger agreement with Remix Therapeutics, Inc., expected to close in Q4 2026.
• The company is winding down its gene therapy programs and terminating related development and supply agreements.
• For the three months ended June 30, 2026, Passage Bio reported a net loss of $7.8 million, or $2.44 per share.
• For the six months ended June 30, 2026, the net loss was $15.4 million, or $4.80 per share.
• As of June 30, 2026, the company had $24.2 million in cash and cash equivalents, with substantial doubt about its ability to continue as a going concern.
• The merger with Remix is expected to result in pre-Merger Remix equity holders owning approximately 65% of the combined company, Passage Bio stockholders approximately 6%, and concurrent financing investors approximately 29%.
• The company has recognized net gains on lease terminations totaling $1.9 million for the three months ended June 30, 2026, and $2.6 million for the six months ended June 30, 2026, related to office and laboratory space.
• A significant workforce reduction of approximately 75% was initiated in April 2026 to decrease operating expenses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing losses, substantial doubt about its going concern status, and the significant strategic shift involving a merger with Remix Therapeutics, which dilutes existing shareholders.

Positives

• The company has entered into a merger agreement with Remix Therapeutics, which could provide a path forward for the combined entity.
• The merger is expected to be a tax-free reorganization for U.S. federal income tax purposes.
• The company recognized net gains on lease terminations, reducing future operating lease liabilities.
• The company has $24.2 million in cash and cash equivalents as of June 30, 2026, providing some short-term liquidity.

Negatives

• Passage Bio has incurred recurring losses and negative cash flows from operations since inception and expects this to continue.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• The company is winding down its gene therapy programs and terminating key development and supply agreements.
• The merger with Remix will result in significant dilution for existing Passage Bio stockholders, who are expected to own only 6% of the combined company.
• The company reported a net loss of $7.8 million for the three months ended June 30, 2026, and $15.4 million for the six months ended June 30, 2026.
• The company has an accumulated deficit of $720.1 million as of June 30, 2026.
• The company's cash and cash equivalents of $24.2 million may not be sufficient to fund operations for the next twelve months.
• The company is subject to significant costs and management resource diversion related to the proposed merger.

Risks

• Failure to complete the merger with Remix Therapeutics could have material adverse effects on the company.
• The pendency of the merger could adversely affect the company's business, operating results, and financial condition.
• Stockholder litigation could prevent or delay the consummation of the merger.
• The merger exchange ratio is fixed by formula and does not adjust for market price fluctuations of Passage Bio's common stock, potentially leading to different values than negotiated.
• There is no assurance that Passage Bio will receive any payments under the Gemma Sublicenses or realize value from its legacy assets, meaning pre-Merger stockholders may not receive value from the Contingent Value Rights.
• Certain directors and executive officers have interests in the merger that may differ from other stockholders.
• The company's current stockholders will have a reduced ownership and voting interest in the combined company.
• The company's ability to obtain future financing may be hindered by the uncertainty of its going concern status.

Future Outlook

The company expects to continue to incur net losses and negative cash flows from operations for the foreseeable future. Its ability to continue as a going concern is dependent on the completion of the merger with Remix Therapeutics and its associated financing, or obtaining substantial additional funding. The company has initiated a review of strategic alternatives and a significant workforce reduction to decrease operating expenses.

Management Comments

• The company has determined to wind-down its gene therapy programs and is entering into a merger agreement with Remix Therapeutics.
• The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes and is expected to close in the fourth quarter of 2026.
• The company has incurred recurring losses and negative cash flows from operations since inception and expects to continue to do so.
• There is substantial doubt about the company's ability to continue as a going concern within one year after the date the consolidated financial statements are issued.
• The company expects its research and development expenses to decrease in the future due to the winding down of its development programs.
• The company expects its general and administrative expenses to decrease in the future due to reductions in leased facilities, staff, and consulting services.

Industry Context

StockSavvy.ai notes that Passage Bio's strategic pivot and wind-down of gene therapy programs reflect the high-risk, capital-intensive nature of early-stage biotechnology. The focus on a merger with Remix Therapeutics suggests a consolidation trend or a search for a more viable path to market for the combined entity's pipeline, potentially in a different therapeutic area.

Comparison to Industry Standards

• The company's net loss of $7.8 million for the quarter and $15.4 million for the six months ended June 30, 2026, is substantial for a clinical-stage company, but not uncommon in the biotech sector where significant R&D investment is required.
• The cash burn rate, leading to a going concern warning, is a critical factor for investors in the biotech industry. Companies often rely on frequent capital raises or strategic transactions like mergers to survive.
• The decision to wind down programs and pursue a merger is a common strategy for biotech firms facing financial challenges or pipeline setbacks, aiming to preserve value or pivot to a more promising area, as seen with other companies in the gene therapy and rare disease space.

Legal Proceedings

• The company is a defendant in litigation with a former employee regarding breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The case involves a dispute over stock settlement terms. The Pennsylvania Supreme Court has agreed to hear a question regarding mediation privilege, with the hearing timing pending. The company intends to continue its defense.

Stakeholder Impact

• Shareholders will experience significant dilution, with their ownership in the combined company expected to be approximately 6%.
• Shareholders may not realize value from the Contingent Value Rights if legacy assets do not generate payments.
• Employees face uncertainty due to the workforce reduction and the pending merger.
• Creditors and suppliers may be impacted by the company's financial condition and strategic shift.

Next Steps

• Complete the merger with Remix Therapeutics, Inc., expected in the fourth quarter of 2026.
• Obtain stockholder approval for the merger and related transactions.
• Continue to wind down gene therapy programs and associated agreements.
• Manage remaining operations and expenses following workforce reduction.

Key Dates

Recommendation

The company faces substantial going concern risks, is winding down its core operations, and the proposed merger involves significant dilution for existing shareholders. While the merger offers a potential path forward, the current financial instability and strategic pivot suggest a high level of risk for investors.

Keywords

Merger Agreement, Remix Therapeutics, Gene Therapy, Neurodegenerative Diseases, Restructuring, Going Concern, Clinical Stage, Financial Statements